News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Radius (RDUS) Announces Presentations At The American Society for Bone and Mineral Research 2014 Annual Meeting


8/19/2014 7:15:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Aug. 19, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that it will present new data from multiple studies of abaloparatide in women with postmenopausal osteoporosis at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, which takes place September 12-15, 2014 in Houston, Texas.

The company will be presenting a responder analysis of the effects of abaloparatide and teriparatide on bone mineral density in postmenopausal women with osteoporosis, as well as additional data from multiple preclinical studies. Abstracts summarizing the abaloparatide data are published on the ASBMR website and are available to conference registrants and ASBMR members at: http://www.asbmr.org/ASBMR-abstracts.

Abstracts related to Radius Health include:

Title: Responder Analysis of the Effects of Abaloparatide and Teriparatide on Bone Mineral Density in Postmenopausal Women With Osteoporosis
Abstract #: FR0379
Presentation date/time: September 12, 5:30 PM - 7:00 PM
Session: Welcome Reception & Plenary Poster Session
Room/Details: Discovery Hall-Hall E/George R. Brown Convention Center
Title: Responder Analysis of the Effects of Abaloparatide and Teriparatide on Bone Mineral Density in Postmenopausal Women With Osteoporosis
Abstract #: SA0379
Presentation date/time: September 13, 12:30 PM - 2:30 PM
Session: Poster Session I & Poster Tours
Room/Details: Discovery Hall-Hall E/George R. Brown Convention Center
Title:Model Abaloparatide (BA058), a Human PTHrP Analog: Correlation of In Vivo Bone Mass Gains and Improved Bone Strength in an Osteopenic Rat Model
Abstract #: SU0370
Presentation date/time: September 14, 12:30 PM - 2:30 PM
Session: Poster Session II & Poster Tours
Room/Details: Discovery Hall-Hall E/George R. Brown Convention Center
Title: Abaloparatide (BA058), a Human PTHrP Analog: Correlation of In Vivo Bone Mass Gains and Improved Bone Strength in the Osteopenic Cynomolgus Monkey
Abstract #: SU0371
Presentation date/time: September 14, 12:30 PM - 2:30 PM
Session: Poster Session I & Poster Tours
Room/Details: Discovery Hall-Hall E/George R. Brown Convention Center
Title: Comparing the Incidence of Bone Tumors in Rats Chronically Exposed to Abaloparatide (BA058) or PTH(1-34)
Abstract #: MO0073
Presentation date/time: September 15, 12:30 PM - 2:30 PM
Session: Poster Session III & Poster Tours
Room/Details: Discovery Hall-Hall E/George R. Brown Convention Center
Title: The Long Term Effects Of Abaloparatide (BA058) On Bone Histomorphometry in Osteopenic Rats
Abstract #: MO0385
Presentation date/time: September 15, 12:30 PM - 2:30 PM
Session: Poster Session III & Poster Tours
Room/Details: Discovery Hall-Hall E/George R. Brown Convention Center
Title: The Long Term Effects Of Abaloparatide (BA058) On Micro-CT and Histomorphometry in Osteopenic Cynomolgus Monkeys
Abstract #: 1050
Presentation date/time: September 13, 3:45 PM - 4:00 PM
Session: Concurrent Orals: Osteoporosis Treatment
Room/Details: Grand Ballroom BC/George R. Brown Convention Center

About Abaloparatide

Abaloparatide (BA058) is a novel synthetic peptide analog of human parathyroid hormone-related protein (hPTHrP), a naturally occurring bone-building hormone that we believe has the potential to increase bone mineral density by stimulating new bone formation. Unlike parathyroid hormone (PTH), hPTHrP is critical in the formation of the skeleton, is involved in the regulation of bone formation and is able to rebuild bone with lower associated risk of inducing the presence of too much calcium in the blood, known as hypercalcemia, as a side effect. Abaloparatide SC is in Phase 3 development as a daily self-administered injection for the treatment of patients with postmenopausal osteoporosis at high risk of fracture. Topline results from an ongoing Phase 3 pivotal trial comparing Abaloparatide SC daily injection to placebo and an active comparator for the prevention of new vertebral fractures are expected at the end of 2014. Radius is also developing Abaloparatide TD, a short wear-time transdermal patch designed to administer abaloparatide without the need for subcutaneous injection, based on 3M's patented Microstructured Transdermal System technology.

About Radius Health

Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases. The company's lead development candidate is abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an abaloparatide transdermal patch for osteoporosis and RAD1901 for estrogen-driven breast cancer brain metastases. www.radiuspharm.com

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding Radius Health's expectations regarding the benefits of Abaloparatide (BA058) and the availability of topline results from an ongoing Phase 3 pivotal trial. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that Radius Health has incurred significant losses since its inception and expects to incur losses for the foreseeable future; Radius Health's need for additional funding, which may not be available; the failure by Radius Health to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of Radius Health's proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that Radius Health may lack the financial resources and access to capital to fund our operations. These and other important factors discussed under the caption "Risk Factors" in the Quarterly Report on Form 10-Q filed by Radius Health with the Securities and Exchange Commission, or SEC, on August 12, 2014, and other reports filed by Radius Health with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

CONTACT: Investor Relations Barbara Ryan FTI Consulting Managing Director 212-850-5679 Barbara.Ryan@fticonsulting.com Media Relations Kimberly Ha FTI Consulting Senior Director 212-850-5612 Kimberly.Ha@fticonsulting.com Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES